MedPath

Gefitinib

Generic Name
Gefitinib
Brand Names
Iressa, Gefitinib Mylan
Drug Type
Small Molecule
Chemical Formula
C22H24ClFN4O3
CAS Number
184475-35-2
Unique Ingredient Identifier
S65743JHBS
Background

Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.

Indication

For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.

Associated Conditions
Metastatic Non-Small Cell Lung Cancer
Associated Therapies
-
Clinical Trials
Related News

Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers

Phase 2
Conditions
Non Small Cell Lung Cancer
Adenocarcinoma
Interventions
Drug: Placebo
Drug: Gefitinib
Drug: Pemetrexed plusCIsplatin
First Posted Date
2011-12-30
Last Posted Date
2012-06-20
Lead Sponsor
National Cancer Center, Korea
Target Recruit Count
162
Registration Number
NCT01502202
Locations
🇰🇷

National Cancer Center, Goyang-si, Gyenggido, Korea, Republic of

Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer

Phase 2
Completed
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
Drug: Gefitinib
Drug: Gefitinib and Nimotuzumab
First Posted Date
2011-12-23
Last Posted Date
2014-12-02
Lead Sponsor
Yonsei University
Target Recruit Count
160
Registration Number
NCT01498562
Locations
🇰🇷

Severance hospital, Yonsei Cancer Center, Seoul, Korea, Republic of

Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy

Phase 2
Completed
Conditions
Squamous Cell Carcinoma of Bronchus
Interventions
Drug: Gefitinib
First Posted Date
2011-12-06
Last Posted Date
2023-11-24
Lead Sponsor
Seoul Veterans Hospital
Target Recruit Count
36
Registration Number
NCT01485809
Locations
🇰🇷

Seoul Veterans Hospital, Seoul, Korea, Republic of

A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

Phase 2
Completed
Conditions
Carcinoma, Non Small Cell Lung
Interventions
Drug: Gefitinib
Drug: Pemetrexed
First Posted Date
2011-11-10
Last Posted Date
2019-09-10
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
195
Registration Number
NCT01469000
Locations
🇨🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Phase 2
Completed
Conditions
Lung Neoplasms
Interventions
Drug: Afatinib
Drug: gefitinib
First Posted Date
2011-11-08
Last Posted Date
2020-04-07
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
319
Registration Number
NCT01466660
Locations
🇫🇷

CTR Leon Berard, Lyon, France

🇬🇧

Western General Hospital, Edinburgh, United Kingdom

🇨🇳

Cancer Hospital of Chinese Academy of Medical Science, Beijing, China

and more 60 locations

Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation

Phase 3
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: Vinorelbine+Cisplatin
Drug: Gefitinib
First Posted Date
2011-07-29
Last Posted Date
2020-02-18
Lead Sponsor
Guangdong Association of Clinical Trials
Target Recruit Count
222
Registration Number
NCT01405079
Locations
🇨🇳

Guangdong General Hospital, Guangzhou, China

Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib

Phase 2
Terminated
Conditions
Head and Neck Cancer
Lung Cancer
Interventions
Drug: Gefitinib
First Posted Date
2011-07-29
Last Posted Date
2016-08-19
Lead Sponsor
Papworth Hospital NHS Foundation Trust
Target Recruit Count
32
Registration Number
NCT01405846
Locations
🇬🇧

Papworth Hospital NHS Trust, Papworth Everard, Cambs, United Kingdom

Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer

Phase 3
Completed
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: Gefitinib
Drug: Gemcitabine +Carboplatin
First Posted Date
2011-07-28
Last Posted Date
2017-01-27
Lead Sponsor
Guangdong Association of Clinical Trials
Target Recruit Count
219
Registration Number
NCT01404260
Locations
🇨🇳

Shanghai Lung Tumor Clinical Center,Shanghai Chest Hospital, Shanghai, Shanghai, China

Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis

Not Applicable
Terminated
Conditions
EGFR-mutated Lung Adenocarcinoma
Brain Metastasis
Interventions
Other: whole brain radiotherapy
Drug: Gefitinib (IRESSA)
First Posted Date
2011-06-01
Last Posted Date
2014-05-13
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
1
Registration Number
NCT01363557
Locations
🇫🇷

Service de Neurologie - Hôpital Avicenne, Bobigny, France

Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma

Phase 2
Terminated
Conditions
Glioblastoma
Interventions
Drug: cediranib maleate
Drug: Placebo
Drug: gefitinib
First Posted Date
2011-03-09
Last Posted Date
2017-05-31
Lead Sponsor
University College, London
Target Recruit Count
38
Registration Number
NCT01310855
Locations
🇬🇧

Bristol Haematology and Oncology Centre, Bristol, United Kingdom

🇬🇧

Southampton General Hospital, Southampton, United Kingdom

🇬🇧

Royal Marsden Hospital, Sutton, United Kingdom

and more 7 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy